Roctavian

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

valoctocogene roxaparvovec

Available from:

BioMarin International Limited

ATC code:

B02BD15

INN (International Name):

Valoctocogene roxaparvovec

Therapeutic group:

Antihemoragije

Therapeutic indications:

Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

Product summary:

Revision: 3

Authorization status:

Pooblaščeni

Authorization date:

2022-08-24

Patient Information leaflet

                                35
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Zdravilo shranjujte in prevažajte zamrznjeno pri ≤ −60 °C.
Shranjujte v originalni škatli za zagotovitev zaščite pred
svetlobo.
Shranjujte v pokončnem položaju.
Odmrznjenega zdravila ne zamrzujte znova.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
To zdravilo vsebuje gensko spremenjene organizme.
Zavrzite v skladu z lokalnimi smernicami za farmacevtske odpadke.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
BioMarin International Ltd.
Shanbally, Ringaskiddy, County Cork
P43 R298, Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/22/1668/001
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
36
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
OZNAKA NA VIALI
1.
IME ZDRAVILA IN POT(I) UPORABE
ROCTAVIAN 2 × 10
13
vektorskih genomov/ml, raztopina za infundiranje
valoktokogen roksaparvovek
Intravenska uporaba
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
8 ml
6.
DRUGI PODATKI
37
B. NAVODILO ZA UPORABO
38
NAVODILO ZA UPORABO
ROCTAVIAN 2 × 10
13 VEKTORSKIH GENOMOV/ML, RAZTOPINA ZA INFUNDIRANJE
valoktokogen roksaparvovek
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Tudi sami lahko k temu prispevate tako, da
poročate o katerem koli neželenem
učinku zdravila, ki bi se utegnil pojaviti pri vas. Glejte na koncu
poglavja 4, kako poročati o neželenih
učinkih.
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
‑
Navodilo shranite. Morda ga bost
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o
katerem koli domnevnem
neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o
neželenih učinkih.
1.
IME ZDRAVILA
ROCTAVIAN 2 × 10
13
vektorskih genomov/ml, raztopina za infundiranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
2.1
SPLOŠEN OPIS
Valoktokogen roksaparvovek je zdravilo za gensko zdravljenje, ki
izraža obliko SQ humanega
koagulacijskega faktorja VIII z izpuščeno domeno B (hFVIII-SQ). Gre
za rekombinanten vektor na
osnovi z adenovirusi povezanih virusov serotipa 5, AAV5, ki ni zmožen
podvajanja in vsebuje cDNA
gena oblike SQ humanega koagulacijskega faktorja VIII z izpuščeno
domeno, nadzira pa ga promotor,
specifičen za jetrne celice.
Valoktokogen roksaparvovek je proizveden v sistemu izražanja
bakulovirusa, ki je pridobljen iz celic
žuželke
_Spodoptera frugiperda_
(celična linija Sf9) s tehnologijo rekombinantne DNA.
2.2
KAKOVOSTNA IN KOLIČINSKA SESTAVA
En ml raztopine za infundiranje valoktokogen roksaparvoveka vsebuje 2
× 10
13
vektorskih genomov.
Ena viala vsebuje 16 × 10
13
vektorskih genomov valoktokogen roksaparvoveka v 8-ml raztopini.
Pomožna snov z znanim učinkom:
To zdravilo vsebuje 29 mg natrija na vialo.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Raztopina za infundiranje.
Prozorna, brezbarvna do bledo rumena raztopina s pH 6,9–7,8 in
osmolarnostjo 364–445 mOsm/l.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo ROCTAVIAN je indicirano za zdravljenje hude hemofilije A
(prirojenega pomanjkanja
faktorja VIII) pri odraslih, ki v preteklosti niso imeli zaviralcev
faktorja VIII in nimajo zaznanih
protiteles proti serotipu 5 z adenovirusi povezanih virusov (AAV5).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje je treba uvesti pod nadzorom zdravnika z izkušnjami pri
zdravljenju hemofilije in/ali
motenj krvavenja. 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-09-2023
Public Assessment Report Public Assessment Report Bulgarian 01-01-1970
Patient Information leaflet Patient Information leaflet Spanish 12-09-2023
Public Assessment Report Public Assessment Report Spanish 01-01-1970
Patient Information leaflet Patient Information leaflet Czech 12-09-2023
Public Assessment Report Public Assessment Report Czech 01-01-1970
Patient Information leaflet Patient Information leaflet Danish 12-09-2023
Public Assessment Report Public Assessment Report Danish 01-01-1970
Patient Information leaflet Patient Information leaflet German 12-09-2023
Public Assessment Report Public Assessment Report German 01-01-1970
Patient Information leaflet Patient Information leaflet Estonian 12-09-2023
Public Assessment Report Public Assessment Report Estonian 01-01-1970
Patient Information leaflet Patient Information leaflet Greek 12-09-2023
Public Assessment Report Public Assessment Report Greek 01-01-1970
Patient Information leaflet Patient Information leaflet English 12-09-2023
Public Assessment Report Public Assessment Report English 01-01-1970
Patient Information leaflet Patient Information leaflet French 12-09-2023
Public Assessment Report Public Assessment Report French 01-01-1970
Patient Information leaflet Patient Information leaflet Italian 12-09-2023
Public Assessment Report Public Assessment Report Italian 01-01-1970
Patient Information leaflet Patient Information leaflet Latvian 12-09-2023
Public Assessment Report Public Assessment Report Latvian 01-01-1970
Patient Information leaflet Patient Information leaflet Lithuanian 12-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-09-2023
Public Assessment Report Public Assessment Report Lithuanian 01-01-1970
Patient Information leaflet Patient Information leaflet Hungarian 12-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 12-09-2023
Public Assessment Report Public Assessment Report Hungarian 01-01-1970
Patient Information leaflet Patient Information leaflet Maltese 12-09-2023
Public Assessment Report Public Assessment Report Maltese 01-01-1970
Patient Information leaflet Patient Information leaflet Dutch 12-09-2023
Public Assessment Report Public Assessment Report Dutch 01-01-1970
Patient Information leaflet Patient Information leaflet Polish 12-09-2023
Public Assessment Report Public Assessment Report Polish 01-01-1970
Patient Information leaflet Patient Information leaflet Portuguese 12-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 12-09-2023
Public Assessment Report Public Assessment Report Portuguese 01-01-1970
Patient Information leaflet Patient Information leaflet Romanian 12-09-2023
Public Assessment Report Public Assessment Report Romanian 01-01-1970
Patient Information leaflet Patient Information leaflet Slovak 12-09-2023
Public Assessment Report Public Assessment Report Slovak 01-01-1970
Patient Information leaflet Patient Information leaflet Finnish 12-09-2023
Public Assessment Report Public Assessment Report Finnish 01-01-1970
Patient Information leaflet Patient Information leaflet Swedish 12-09-2023
Public Assessment Report Public Assessment Report Swedish 01-01-1970
Patient Information leaflet Patient Information leaflet Norwegian 12-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 12-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 12-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 12-09-2023
Patient Information leaflet Patient Information leaflet Croatian 12-09-2023
Public Assessment Report Public Assessment Report Croatian 01-01-1970

Search alerts related to this product

View documents history